Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 6/20 | 0.44 |
| ▸ | ITK | Q08881 | 6/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.42 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15673229 | 1.00 | PIK3CD (0.44) | PIK3CDLCKITKROCK2USP30 | |
| SCHEMBL8739811 | 0.88 | LCK (0.43) | LCKITKROCK2USP30OTUD7B | |
| SCHEMBL29470391 | 0.88 | LCK (0.43) | LCKITKROCK2USP30OTUD7B | |
| SCHEMBL15673410 | 0.86 | LCK (0.43) | LCKITKROCK2USP30OTUD7B | |
| SCHEMBL29470459 | 0.85 | LCK (0.43) | LCKITKROCK2USP30OTUD7B | |
| SCHEMBL15673378 | 0.85 | LCK (0.43) | LCKITKROCK2USP30OTUD7B | |
| SCHEMBL8739830 | 0.85 | LCK (0.43) | LCKITKROCK2USP30OTUD7B | |
| SCHEMBL15673347 | 0.85 | LCK (0.43) | LCKITKROCK2USP30OTUD7B | |
| SCHEMBL29470323 | 0.85 | LCK (0.43) | LCKITKROCK2USP30OTUD7B | |
| SCHEMBL15673489 | 0.82 | LCK (0.44) | LCKITKROCK2USP30OTUD7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773110-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | PIK3CD 3580/4885LCK 212/4885ITK 829/4885 |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | PIK3CD 3580/4885LCK 212/4885ITK 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.